Eli Lilly’s evaluation agreement with Peptron, extended through October 7, 2026, remains limited to non-binding joint research on applying SmartDepot microsphere formulations to peptide candidates, including GLP-1 agents. This stage grants only an internal R&D license and permits termination on 30 days’ notice, with no commercial rights transferred. No binding technology transfer or licensing deal granting development, manufacturing, or sales rights has been announced, while Lilly advances alternative long-acting platforms such as Camurus’ FluidCrystal. Ongoing in-vivo studies and Peptron’s recent GLP-1 patent filings and manufacturing expansion have not shifted the timeline toward commercialization by the deadline. Traders see strong consensus around “No” because any last-minute surprise would require rapid execution of a full commercial agreement in the final 48 hours.